ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb has struck separate agreements to license BMS-986168, an anti-eTau compound in development for progressive supranuclear palsy, to Biogen and BMS-986089, an antimyostatin adnectin in development for Duchenne muscular dystrophy, to Roche. Biogen will pay $300 million plus milestones of up to $410 million. Roche will pay $170 million plus milestones of up to $205 million. BMS says the deals will allow it to prioritize other drugs in its pipeline. It got BMS-986168 with its 2014 acquisition of iPierian.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X